JDR JDR Most Cited Articles
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Götrick, B.
Right arrow Articles by Tobin, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Götrick, B.
Right arrow Articles by Tobin, G.
J Dent Res 83(5): 393-397, 2004
© 2004 International and American Associations for Dental Research


RESEARCH REPORT
Clinical

Oral Pilocarpine for Treatment of Opioid-induced Oral Dryness in Healthy Adults

B. Götrick1,*, S. Åkerman2, D. Ericson3, R. Torstenson4, and G. Tobin5

1 Department of Hospital Dentistry and
4 Hospital Pharmacy, Malmö University Hospital, SE-205 02 Malmö, Sweden;
2 Department of Oral Diagnostics and
3 Department of Cariology, Faculty of Odontology, Malmö University, SE-205 06 Malmö, Sweden; and
5 Department of Pharmacology, Göteborg University, Box 431, SE-405 30 Göteborg, Sweden;

* corresponding author, bengt.gotrick{at}skane.se

Pilocarpine induces a profuse flow of saliva when administered orally, but effects on drug-induced oral dryness have not been examined. The aim of this trial was to investigate if pilocarpine increases production of saliva in individuals suffering from dry mouth due to treatment with opioids. Sixty-five individuals were enrolled in a randomized, double-blind, placebo-controlled trial. The subjects received tramadol (50 mg t.d.s.) to induce oral dryness, and were thereafter assigned to one of three groups. Secretion rate of saliva was measured before and after tramadol, and after the oral administration of pilocarpine (5 mg), placebo, or no treatment. Baseline characteristics did not differ among the groups (mean ± SEM: 0.37 ± 0.06 mL/min), and tramadol lowered the secretion at the same level in all groups (0.15 ± 0.02 mL/min). Pilocarpine increased the flow above that observed with placebo (0.66 ± 0.19 vs. 0.15 ± 0.02 mL/min). Thus, pilocarpine re-establishes the flow of saliva in the state of tramadol-induced oral dryness.

KEY WORDS: pilocarpine • oral dryness • randomized controlled trial • drug-induced xerostomia




This article has been cited by other articles:


Home page
J. Dent. Res.Home page
N. Sato, K. Ono, E. Honda, K. Haga, M. Yokota, and K. Inenaga
Pilocarpine-induced Salivation and Thirst in Conscious Rats
J. Dent. Res., January 1, 2006; 85(1): 64 - 68.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
K. J. MASTERS
Pilocarpine Treatment of Xerostomia Induced by Psychoactive Medications
Am J Psychiatry, May 1, 2005; 162(5): 1023 - 1023.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
IADR Journals Advances in Dental Research ®
Journal of Dental Research ® Critical Reviews (1990-2004)
Copyright © 2004 Institutional Access Guidelines